Aligos Therapeutics Inc. (ALGS)
NASDAQ · Healthcare
Aligos Therapeutics Inc. annual/quarterly shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Aligos Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 53.5M, a 284.81% decrease year-over-year.
- Aligos Therapeutics Inc. shareholder equity for 2025 were 53.5M, a 284.81% decrease from 2024.
- Aligos Therapeutics Inc. shareholder equity for 2024 were -29.0M, a 131.47% decrease from 2023.
- Aligos Therapeutics Inc. shareholder equity for 2023 were 92.1M, a 11.38% decrease from 2022.
- Aligos Therapeutics Inc. shareholder equity for 2022 were 103.9M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Aligos Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $54 |
| 2024 | $-29 |
| 2023 | $92 |
| 2022 | $104 |
| 2021 | $185 |
| 2020 | $220 |
| Aligos Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $54 |
| 2024-12-31 | $-29 |
| 2023-12-31 | $92 |
| 2022-12-31 | $104 |
| 2021-12-31 | $185 |
| 2020-12-31 | $220 |
Aligos Therapeutics Inc. Shareholder Equity — FAQ
Aligos Therapeutics Inc. (ALGS) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ALGS's shareholder equity history?
The chart and table above show Aligos Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.